AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6376292 — intervention group
Group type: COMPARATOR
Intervention: High dose cimetidine after crossover
Number of subjects: 25
Study 6376292 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 25
Study 30653704 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose alone (n=147)
Number of subjects: 446
Study 30653704 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose plus TeleCare (n=148)
Number of subjects: 446
Study 30653704 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual diabetes care (n=151)
Number of subjects: 446
Study 30653704 — intervention group
Group type: COMPARATOR
Intervention: Structured self-monitoring of blood glucose compared to control group
Number of subjects: 446
Study 29281941 — intervention group
Group type: EXPERIMENTAL
Intervention: Action planning and coping planning intervention strategies; duration: 105 days; includes in-person meetings and phone calls to reinforce the intervention.
Number of subjects: 0
Study 29281941 — intervention group
Group type: COMPARATOR
Intervention: Usual care from the health unit; duration: 105 days.
Number of subjects: 0
Study 25040485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital value‐based purchasing (HVBP) program
Number of subjects: 0
Study 25040485 — intervention group
Group type: COMPARATOR
Intervention: Nonexposed hospitals (control group)
Number of subjects: 0
Study 24056820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 1
Study 24056820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 24056820 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 1
Study 19638470 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 16923435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 199) received optimized nonpharmacological and pharmacological cardiovascular treatments by a geriatrician according to guidelines.
Number of subjects: 400
Study 16923435 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 201) received usual care.
Number of subjects: 400
Study 17076970 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1636
Study 17076970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1636
Study 11212063 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 199
Study 11212063 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg
Number of subjects: 199
Study 11212063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 11212063 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine or Felodipine
Number of subjects: 199
Study 8859608 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline 0.9% rinses
Number of subjects: 0
Study 8859608 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen peroxide 3.5 volumes (HP) rinses
Number of subjects: 0
Study 1643912 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine inhalation challenge (MIC)
Number of subjects: 40
Study 1643912 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperventilation (EVH) with dry gas
Number of subjects: 40
Study 1643912 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperventilation (EVH) with cold gas
Number of subjects: 40
Study 1643912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometer challenge
Number of subjects: 40
Study 1643912 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves for EVH techniques and MIC
Number of subjects: 40
Study 6825410 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest cage restriction (strapped in the position of full expiration)
Number of subjects: 6
Study 6825410 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing without chest cage restriction (control)
Number of subjects: 6
Study 30506299 — intervention group
Group type: COMPARATOR
Intervention: PCEA
Number of subjects: 200
Study 30506299 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB
Number of subjects: 200
Study 30144554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptogenic cirrhosis
Number of subjects: 247
Study 30144554 — intervention group
Group type: COMPARATOR
Intervention: NASH cirrhosis
Number of subjects: 247
Study 27339251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus feeding (Group A)
Number of subjects: 40
Study 27339251 — intervention group
Group type: COMPARATOR
Intervention: Continuous feeding (Group B)
Number of subjects: 40
Study 24170758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for adherence and depression (CBT-AD)
Number of subjects: 87
Study 22038792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg) once daily
Number of subjects: 104
Study 20386475 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g arginine + 300 mg grape seed extract
Number of subjects: 50
Study 20386475 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g arginine + 300 mg grape seed extract
Number of subjects: 50
Study 20386475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 50
Study 18339679 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin on alternate days
Number of subjects: 37270
Study 18339679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37270
Study 15963082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 20
Study 15963082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily plus famotidine 20 mg twice daily
Number of subjects: 20
Study 15963082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12908901 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental intakes of 0.3, 1.0 and 2.0 g EPA+DHA/d
Number of subjects: 16
Study 12908901 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant co-supplementation (200 microg Se, 3 mg Mn, 30 mg D-alpha-tocopheryl succinate, 90 mg ascorbic acid, 450 microg vitamin A)
Number of subjects: 16
Study 12908901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10232721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 80
Study 10232721 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 80
Study 8916621 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 sessions of time-limited psychotherapy
Number of subjects: 212
Study 8916621 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 sessions of time-limited psychotherapy
Number of subjects: 212
Study 8916621 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 8 and 16 sessions
Number of subjects: 212
Study 1865542 — intervention group
Group type: EXPERIMENTAL
Intervention: E5 murine monoclonal antibody (2 mg/kg)
Number of subjects: 486
Study 1865542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study 31727667 — intervention group
Group type: EXPERIMENTAL
Intervention: Choosing Wisely Australia 5 Questions resource and preparation video
Number of subjects: 0
Study 31727667 — intervention group
Group type: COMPARATOR
Intervention: Choosing Wisely Australia 5 Questions resource
Number of subjects: 0
Study 31727667 — intervention group
Group type: COMPARATOR
Intervention: Preparation video
Number of subjects: 0
Study 28625860 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 71
Study 28625860 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 71
Study 25926387 — intervention group
Group type: COMPARATOR
Intervention: Serum eicosapentaenoic acid (EPA)
Number of subjects: 438
Study 25926387 — intervention group
Group type: COMPARATOR
Intervention: Serum docosahexaenoic acid (DHA)
Number of subjects: 438
Study 25926387 — intervention group
Group type: COMPARATOR
Intervention: Serum linoleic acid
Number of subjects: 438
Study 25926387 — intervention group
Group type: COMPARATOR
Intervention: Serum trans fatty acids
Number of subjects: 438
Study 25926387 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum arachidonic acid
Number of subjects: 438
Study 23799810 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 23799810 — intervention group
Group type: COMPARATOR
Intervention: Active reference treatment
Number of subjects: 0
Study 23799810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20936566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry state (hot)
Number of subjects: 0
Study 20936566 — intervention group
Group type: COMPARATOR
Intervention: Satiated state (cold)
Number of subjects: 0
Study 20639717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730 (probiotic supplementation)
Number of subjects: 0
Study 20639717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 18437790 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate or early loaded implants
Number of subjects: 22
Study 18437790 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading period
Number of subjects: 22
Study 15134615 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha inhibitors (etanercept and infliximab)
Number of subjects: 31
Study 15134615 — intervention group
Group type: COMPARATOR
Intervention: No TNF-alpha inhibition therapy (Control Group 2)
Number of subjects: 31
Study 12351257 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 200/0.5 (HES)
Number of subjects: 60
Study 12351257 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% modified gelatin (GEL)
Number of subjects: 60
Study 12351257 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (RL)
Number of subjects: 60
Study 9647031 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine 4 g/day
Number of subjects: 0
Study 9647031 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine 8 g/day
Number of subjects: 0
Study 9647031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7807504 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10-40 mg twice daily) in Study I; titrated every 1-2 weeks for 6 weeks, followed by 6 weeks of therapy.
Number of subjects: 172
Study 7807504 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (5-20 mg twice daily) in Study II; titrated every 4 weeks for 16 weeks, followed by a 12-week maintenance period.
Number of subjects: 172
Study 2642814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Novum 777 (norethindrone)
Number of subjects: 61
Study 2642814 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasil (levonorgestrel)
Number of subjects: 61
Study 790547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 150 mg daily
Number of subjects: 38
Study 790547 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone 300 mg daily
Number of subjects: 38
Study 31190590 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFETY intervention (home-based disease management including community-based AF care and home visits)
Number of subjects: 335
Study 31190590 — intervention group
Group type: COMPARATOR
Intervention: Standard management (routine primary healthcare and hospital outpatient follow-up)
Number of subjects: 335
Study 28279207 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting To Outcomes (GTO) implementation support strategy
Number of subjects: 0
Study 28279207 — intervention group
Group type: COMPARATOR
Intervention: Implementation as Usual (IU)
Number of subjects: 0
Study 25208649 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal responsiveness rated on a five-point global rating scale (1 = very low responsiveness, 5 = very high responsiveness)
Number of subjects: 301
Study 24427599 — intervention group
Group type: COMPARATOR
Intervention: Myringoplasty only (Group A)
Number of subjects: 120
Study 24427599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical mastoidectomy with myringoplasty (Group B)
Number of subjects: 120
Study 21523849 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals who deliver babies (OBs and MWs)
Number of subjects: 100
Study 21523849 — intervention group
Group type: COMPARATOR
Intervention: Healthcare professionals who only do prenatal consultations (GYNs and GPs)
Number of subjects: 100
Study 19232037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 30 mg
Number of subjects: 83
Study 19232037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg
Number of subjects: 83
Study 19232037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 120 mg
Number of subjects: 83
Study 19232037 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 83
Study 19232037 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg
Number of subjects: 83
Study 16428050 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-phase contrast medium injection (Group 1)
Number of subjects: 244
Study 16428050 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-phase contrast medium injection (Group 2)
Number of subjects: 244
Study 16428050 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-phase injection (Group 3)
Number of subjects: 244
Study 14527372 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 54
Study 14527372 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 54
Study 10636157 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal selegiline
Number of subjects: 0
Study 10636157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8884561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 12
Study 8884561 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 12
Study 8884561 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (150 mg)
Number of subjects: 12
Study 8884561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1362843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifonazole shampoo
Number of subjects: 44
Study 1362843 — intervention group
Group type: COMPARATOR
Intervention: Vehicle shampoo
Number of subjects: 44
Study 3910546 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg four times a day
Number of subjects: 40
Study 3910546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31885221 — intervention group
Group type: EXPERIMENTAL
Intervention: RUSF
Number of subjects: 485
Study 31885221 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 485
Study 31885221 — intervention group
Group type: EXPERIMENTAL
Intervention: Low consumers of RUSF
Number of subjects: 485
Study 31885221 — intervention group
Group type: COMPARATOR
Intervention: CSB++ or MNP
Number of subjects: 485
Study 30079863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine preloading with a 21 mg/24 hour nicotine patch for 4 weeks prior to quit date
Number of subjects: 1792
Study 30079863 — intervention group
Group type: COMPARATOR
Intervention: Control group received equivalent behavioral support
Number of subjects: 1792
Study 27197192 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and chemotherapy
Number of subjects: 48
Study 24766817 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 24766817 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 0
Study 22290743 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (4.6 mg/24 hours for 3 weeks)
Number of subjects: 12
Study 22290743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21336011 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective measurement via Hot Flash Diary Report
Number of subjects: 100
Study 21336011 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measurement using Mexameter, Skin Thermometer, Corneometer, and LDPI
Number of subjects: 100
Study 19020639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% drops (1 drop given preoperatively)
Number of subjects: 85
Study 19020639 — intervention group
Group type: COMPARATOR
Intervention: Placebo (balanced saline solution, 1 drop given preoperatively)
Number of subjects: 85
Study 19020639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% drops
Number of subjects: 85
Study 19020639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 16363755 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Vaginal Hysterectomy (TVH)
Number of subjects: 158
Study 16363755 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal Sacrospinous Uterine Suspension (SSUS)
Number of subjects: 158
Study 12063524 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 47
Study 12063524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 10328861 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset/rime segmentation
Number of subjects: 0
Study 10328861 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonemic segmentation
Number of subjects: 0
Study 10328861 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole word repetition
Number of subjects: 0
Study 10328861 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset/rime training
Number of subjects: 0
Study 10328861 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoneme training
Number of subjects: 0
Study 10328861 — intervention group
Group type: EXPERIMENTAL
Intervention: Word level training
Number of subjects: 0
Study 8577211 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin after low protein breakfast
Number of subjects: 17
Study 8577211 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin after low fat breakfast
Number of subjects: 17
Study 8577211 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin after low carbohydrate breakfast
Number of subjects: 17
Study 8577211 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin after standard breakfast
Number of subjects: 17
Study 8577211 — intervention group
Group type: COMPARATOR
Intervention: Fasting conditions
Number of subjects: 17
Study 2251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (Parlodel; Sandoz) in doses up to 26 mg daily
Number of subjects: 0
Study 2251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (Parlodel; Sandoz) in doses beyond 25-30 mg daily
Number of subjects: 0
Study 2251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (Parlodel; Sandoz) with slow dose increases
Number of subjects: 0
Study 425546 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoxan
Number of subjects: 8
Study 425546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no considerable treatment)
Number of subjects: 8
Study 31575021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Vitamin A&D supplement (20,000 IU retinyl palmitate and 2000 IU cholecalciferol)
Number of subjects: 79
Study 31575021 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 79
Study 29878061 — intervention group
Group type: EXPERIMENTAL
Intervention: HMBF (0.81 kcal/mL)
Number of subjects: 127
Study 29878061 — intervention group
Group type: COMPARATOR
Intervention: BMBF (0.72 kcal/mL)
Number of subjects: 127
Study 29878061 — intervention group
Group type: EXPERIMENTAL
Intervention: HMBF
Number of subjects: 127
Study 29878061 — intervention group
Group type: COMPARATOR
Intervention: BMBF
Number of subjects: 127
Study 26881417 — intervention group
Group type: COMPARATOR
Intervention: Control group with daily feedback
Number of subjects: 281
Study 26881417 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain incentive ($1.40 for achieving the goal)
Number of subjects: 281
Study 26881417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive (daily eligibility for approximately $1.40 if goal achieved)
Number of subjects: 281
Study 26881417 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss incentive ($42 allocated monthly upfront, $1.40 removed for each day the goal is not achieved)
Number of subjects: 281
Study 25222630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation and multi-family group treatment (CR-MFG)
Number of subjects: 46
Study 25222630 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 46
Study 22828532 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 56
Study 22828532 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 56
Study 22828532 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Methotrexate and Hydroxychloroquine
Number of subjects: 56
Study 20797407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous micafungin (MCFG) 150-300 mg once daily
Number of subjects: 107
Study 20797407 — intervention group
Group type: COMPARATOR
Intervention: Intravenous voriconazole (VRCZ) 6 mg/kg twice on Day 1 followed by 4 mg/kg twice daily
Number of subjects: 107
Study 17908614 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of select cephalosporins (cefpodoxime, cefuroxime, cefotiam, and cefdinir)
Number of subjects: 1030
Study 17908614 — intervention group
Group type: COMPARATOR
Intervention: 10 days of penicillin
Number of subjects: 1030
Study 16231620 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylcholine (PC) coated oxygenators (Group B)
Number of subjects: 40
Study 16231620 — intervention group
Group type: COMPARATOR
Intervention: Non-coated oxygenators (Group A)
Number of subjects: 40
Study 16231620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 40
Study 11867369 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tramadol (150‐mg bolus followed by infusion, total 450 mg/24 h)
Number of subjects: 89
Study 11867369 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg, then 0.2 mg/h)
Number of subjects: 89
Study 11867369 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine only
Number of subjects: 89
Study 11867369 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tramadol
Number of subjects: 89